Paper Details

  1. Home
  2. Paper Details

Long-term effects of weight-reducing drugs in people with hypertension.

Author: BergholdAndrea, HorvathKarl, JeitlerKlaus, KrennCornelia, SemlitschThomas, SiebenhoferAndrea, WinterholerSebastian

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This review found that orlistat, phentermine/topiramate, and naltrexone/bupropion reduced body weight in people with elevated blood pressure, with the greatest effect seen with phentermine/topiramate. Orlistat and phentermine/topiramate also reduced blood pressure, while naltrexone/bupropion did not. One RCT of naltrexone/bupropion versus placebo showed no differences in all-cause mortality or cardiovascular mortality or morbidity after two years.
Paper Details　
Original Abstract of the Article :
BACKGROUND: This is the third update of this review, first published in July 2009. All major guidelines on treatment of hypertension recommend weight loss; anti-obesity drugs may be able to help in this respect. OBJECTIVES: Primary objectives: To assess the long-term effects of pharmacologically-in...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094237/

データ提供：米国国立医学図書館（NLM）

Weight-Reducing Drugs: A Mixed Bag for Hypertension

This research delves into the complex interplay between weight-reducing drugs and hypertension, a common condition affecting millions worldwide. The researchers conducted a comprehensive review of randomized controlled trials to assess the long-term effects of various weight-loss medications on all-cause mortality, cardiovascular morbidity, adverse events, and blood pressure control in adults with hypertension.

A Balancing Act

The analysis revealed mixed results. Some medications like orlistat and phentermine/topiramate showed benefits in reducing body weight and blood pressure. However, naltrexone/bupropion did not demonstrate significant differences in blood pressure control or cardiovascular outcomes compared to placebo. Furthermore, the review highlighted the importance of considering potential adverse events associated with these medications.

Navigating the Weight-Loss Landscape

The study suggests that weight-reducing drugs may play a role in managing hypertension, but their effectiveness and safety profiles vary. Consulting with a healthcare professional is crucial to determine the most appropriate treatment approach based on individual factors like health status, risk tolerance, and specific medication options.

Dr. Camel's Conclusion

Imagine a camel trekking across a vast desert, encountering various obstacles and challenges along the way. Weight-reducing drugs for hypertension are like navigating this desert, where some paths lead to favorable outcomes, while others pose potential risks. Careful consideration and personalized guidance from a healthcare professional are essential for navigating this complex journey.
Date :
  1. Date Completed 2021-02-05
  2. Date Revised 2022-08-31
Further Info :

Pubmed ID

33454957

DOI: Digital Object Identifier

PMC8094237

Related Literature

Article Analysis
・Side Effects of phentermine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.